Revenue: As of FY2025 Q3, the actual value is USD 15 K.

EPS: As of FY2025 Q3, the actual value is USD -0.85.

EBIT: As of FY2025 Q3, the actual value is USD -5.039 M.

Segment Revenue

• Total Revenue: $15,000 for the three months ended September 30, 2025, compared to $87,000 for the same period in 2024, representing an 83% decrease. For the nine months ended September 30, 2025, total revenue was $123,000, compared to $251,000 for the same period in 2024, a 51% decrease.

Operational Metrics

• Loss from Operations: - $5,648,000 for the three months ended September 30, 2025, compared to - $7,815,000 for the same period in 2024, a 28% decrease. For the nine months ended September 30, 2025, the loss from operations was - $15,588,000, compared to - $24,438,000 for the same period in 2024, a 36% decrease.
• Net Loss: - $8,777,000 for the three months ended September 30, 2025, compared to - $7,986,000 for the same period in 2024, a 10% increase. For the nine months ended September 30, 2025, the net loss was - $16,947,000, compared to - $25,851,000 for the same period in 2024, a 34% decrease.

Cash Flow

• Net Cash Used in Operating Activities: - $13,747,000 for the nine months ended September 30, 2025, compared to - $16,461,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $9,448,000 for the nine months ended September 30, 2025, compared to - $4,057,000 used in the same period in 2024.

Unique Metrics

• Research and Development Expense: $3,513,000 for the three months ended September 30, 2025, compared to $4,471,000 for the same period in 2024, a 21% decrease. For the nine months ended September 30, 2025, research and development expenses were $8,508,000, compared to $14,490,000 for the same period in 2024, a 41% decrease.
• General and Administrative Expense: $2,150,000 for the three months ended September 30, 2025, compared to $3,413,000 for the same period in 2024, a 37% decrease. For the nine months ended September 30, 2025, general and administrative expenses were $7,183,000, compared to $10,147,000 for the same period in 2024, a 29% decrease.

Future Outlook and Strategy

• Core Business Focus: The company plans to submit a New Drug Application (NDA) for CNM-Au8 under an accelerated approval pathway in the first quarter of 2026, contingent on positive data from ongoing studies. They also plan to commence a confirmatory Phase 3 trial, RESTORE-ALS, in the first half of 2026, contingent on funding.
• Non-Core Business: The company is exploring additional funding options, including equity financing, debt financing, and collaboration arrangements, to support its operations and strategic initiatives.